Video

Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

Author(s):

Sponsored Content

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Photo of Dr. Prithviraj Bose
Dr. Josh Sabari and Terri Conneran
Dr. Rosario Ligestri
Related Content
Image of a head and neck
September 17th 2025

Understanding Head and Neck Cancer: A Guide for Newly Diagnosed Patients

Gina Mauro
illustration of gynecologic cancer
September 17th 2025

What Does An Early-Stage Gynecologic Cancer Diagnosis Mean?

Ryan Scott
Dr. Paul Gellhaus says PSA testing and modern biopsy methods ease fears and reassure patients, making early prostate cancer detection safe and valuable.
September 17th 2025

Early Prostate Cancer Detection: Why PSA Screening Matters

Dr. Paul Gellhaus
Image of melanoma
September 17th 2025

Early-Stage Melanoma: Diagnosis, Treatment and Next Steps

Ryan Scott
Kristen Dahlgren of the Cancer Vaccine Coalition spoke with CURE about why she remains hopeful for the future or cancer vaccines.
September 17th 2025

Could Cancer Vaccines Become a Reality Within the Next Decade?

Kristen Dahlgren
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
September 17th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam